Michele Carbone to Immunotherapy
This is a "connection" page, showing publications Michele Carbone has written about Immunotherapy.
Connection Strength
1.084
-
Rivera Z, Ferrone S, Wang X, Jube S, Yang H, Pass HI, Kanodia S, Gaudino G, Carbone M. CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma. Clin Cancer Res. 2012 Oct 01; 18(19):5352-63.
Score: 0.392
-
Carbone M. Feasibility of immunotherapy for lymphangioleiomyomatosis. Am J Pathol. 2009 Dec; 175(6):2252-4.
Score: 0.324
-
McCambridge AJ, Napolitano A, Mansfield AS, Fennell DA, Sekido Y, Nowak AK, Reungwetwattana T, Mao W, Pass HI, Carbone M, Yang H, Peikert T. Progress in the Management of Malignant Pleural?Mesothelioma in 2017. J Thorac Oncol. 2018 05; 13(5):606-623.
Score: 0.144
-
Bononi A, Napolitano A, Pass HI, Yang H, Carbone M. Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies. Expert Rev Respir Med. 2015 Oct; 9(5):633-54.
Score: 0.121
-
Bertino P, Panigada M, Soprana E, Bianchi V, Bertilaccio S, Sanvito F, Rose AH, Yang H, Gaudino G, Hoffmann PR, Siccardi A, Carbone M. Fowlpox-based survivin vaccination for malignant mesothelioma therapy. Int J Cancer. 2013 Aug 01; 133(3):612-23.
Score: 0.102